INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
Go back to INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models| (NASDAQ: INMB) | Delayed: 1.43 -0.02 (1.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.45 | 52 Week High | $ | |||
| Open | $1.41 | 52 Week Low | $ | |||
| Day High | $1.48 | P/E | N/A | |||
| Day Low | $1.35 | EPS | $ | |||
| Volume | 284,421 | |||||

